Intelligent Bio Solutions (INBS) Stock Analysis & AI Equity Report
Intelligent Bio Solutions (INBS) overview
Intelligent Bio Solutions (INBS) stock analysis and AI equity research. For financial year 2026, Valuatum's model shows revenue of USD 4.2m and operating profit of USD -12.6m; the year-end share price was 2.30 USD and market capitalisation was USD 6.7m. Intelligent Bio Solutions is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Intelligent Bio Solutions's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Intelligent Bio Solutions
Intelligent Bio Solutions develops and delivers testing and screening solutions, including its Intelligent Fingerprinting Platform, a portable system that analyzes fingerprint sweat using a disposable cartridge and handheld reader. Its commercially available drug screening system is designed to detect several drugs of abuse. The company is also developing applications for the platform and holds biosensor technology licenses and wearable and software-based technologies in its portfolio.
Generate the Intelligent Bio Solutions report
Intelligent Bio Solutions is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Intelligent Bio Solutions and represent financial year 2026. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Intelligent Bio Solutions
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.